Breaking News
Subscribe Now 0
🎈 Up Big Today: Find today's biggest gainers (some over 50%!) with our free screener
Try Stock Screener
Close

Altimmune Inc (3G0)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
6.16 -0.16    -2.53%
13:04:44 - Closed. Currency in EUR
Type:  Equity
Market:  Germany
ISIN:  US02155H2004 
S/N:  A2N5Z6
  • Volume: 2,362
  • Bid/Ask: 6.22 / 6.27
  • Day's Range: 5.99 - 6.19
Altimmune 6.16 -0.16 -2.53%

Altimmune Inc Company Profile

 
Get an in-depth profile of Altimmune Inc, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

52

Equity Type

ORD

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company’s lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.

Contact Information

Address 910 Clopper Road Suite 201S
Gaithersburg, 20878
United States
Phone 240 654 1450
Fax -

Top Executives

Name Age Since Title
Mitchel B. Sayare 73 2010 Independent Chairman
Philip L. Hodges 52 2017 Independent Director
Vipin K. Garg 63 2018 President, CEO & Director
Klaus O. Schafer 74 2017 Independent Director
Diane Kathryn Jorkasky 72 2020 Independent Director
John M. Gill 72 2004 Independent Director
Rohit Loomba - 2022 Member of Mash Scientific Advisory Board
Mazen Noureddin - 2022 Member of Mash Scientific Advisory Board
Catherine Angell Sohn 71 2023 Independent Director
Wayne F. Pisano 69 2018 Independent Director
Caroline M. Apovian - 2022 Member of Obesity Scientific Advisory Board
Louis J. Aronne 68 2022 Member of Obesity Scientific Advisory Board
Robert F. Kushner - 2022 Member of Obesity Scientific Advisory Board
Naga Chalasani - 2022 Member of Mash Scientific Advisory Board
Donna Ryan - 2022 Member of Obesity Scientific Advisory Board
Juan Pablo Frias - 2022 Member of Obesity Scientific Advisory Board
Samuel Klein - 2022 Member of Obesity Scientific Advisory Board
Lee M. Kaplan - 2023 Member of Obesity Scientific Advisory Board
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

ALT Comments

Write your thoughts about Altimmune Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Mason Cutlip
Mason Cutlip Jun 23, 2024 8:28PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
25 then 100 it all starts Monday
Jack Belforte
Jack Belforte Apr 02, 2024 7:00AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Some analysts are missing the bigger picture. ALT may surprise a few skeptics.
Seen see
ThurstonHowell Apr 02, 2024 7:00AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Let's hope Garg can sell.or partner up.
Jack Belforte
Jack Belforte Apr 01, 2024 8:05AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Accumulation showing ALT is back on the map.
Jack Belforte
Jack Belforte Mar 29, 2024 9:27AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Major reversal on ALT due to Wednesday update. Positive investor reaction.
Mason Cutlip
Mason Cutlip Mar 05, 2024 11:42PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
last Chance to get in here.
Jack Belforte
Jack Belforte Feb 22, 2024 8:12AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Sadly ALT is losing investors.
Mason Cutlip
Mason Cutlip Feb 22, 2024 8:12AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
tutes increased their holdings LOL unfortunately Margin Calls and forced liquidation is about to become a reality for shorts
Jack Belforte
Jack Belforte Feb 14, 2024 9:17AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
ALT losing its grip due to viability concerns as well as others.
Jack Belforte
Jack Belforte Feb 13, 2024 6:00AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
ALT may have stalled due to concerns of viability and strong competition. $8-$10
Jack Belforte
Jack Belforte Feb 08, 2024 6:24PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
ALT could rise to the $15 levels
Douglas Langston
Douglas Langston Jan 19, 2024 12:50PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Why are we tanking today?
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Apple
Continue with Google
or
Sign up with Email